312 related articles for article (PubMed ID: 26125431)
21. High-throughput diagnostic profiling of clinically actionable gene fusions in lung cancer.
Pfarr N; Stenzinger A; Penzel R; Warth A; Dienemann H; Schirmacher P; Weichert W; Endris V
Genes Chromosomes Cancer; 2016 Jan; 55(1):30-44. PubMed ID: 26394895
[TBL] [Abstract][Full Text] [Related]
22. Clinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and Gastrointestinal Malignancies.
Fisher KE; Zhang L; Wang J; Smith GH; Newman S; Schneider TM; Pillai RN; Kudchadkar RR; Owonikoko TK; Ramalingam SS; Lawson DH; Delman KA; El-Rayes BF; Wilson MM; Sullivan HC; Morrison AS; Balci S; Adsay NV; Gal AA; Sica GL; Saxe DF; Mann KP; Hill CE; Khuri FR; Rossi MR
J Mol Diagn; 2016 Mar; 18(2):299-315. PubMed ID: 26801070
[TBL] [Abstract][Full Text] [Related]
23. High-resolution melting analysis as a sensitive prescreening diagnostic tool to detect KRAS , BRAF , PIK3CA , and AKT1 mutations in formalin-fixed, paraffin-embedded tissues.
Ney JT; Froehner S; Roesler A; Buettner R; Merkelbach-Bruse S
Arch Pathol Lab Med; 2012 Sep; 136(9):983-92. PubMed ID: 22938585
[TBL] [Abstract][Full Text] [Related]
24. Detection of EGFR mutation in tissue samples of non-small-cell lung cancer by a fluorescence polarization assay.
Liu W; Li X; Zhang Z; Chen Y; Qiang S; Cheng H; Fan L; Liang P; Zhang J
Diagn Mol Pathol; 2012 Sep; 21(3):138-42. PubMed ID: 22847157
[TBL] [Abstract][Full Text] [Related]
25. Clinical Genotyping of Non-Small Cell Lung Cancers Using Targeted Next-Generation Sequencing: Utility of Identifying Rare and Co-mutations in Oncogenic Driver Genes.
Tafe LJ; Pierce KJ; Peterson JD; de Abreu F; Memoli VA; Black CC; Pettus JR; Marotti JD; Gutmann EJ; Liu X; Shirai K; Dragnev KH; Amos CI; Tsongalis GJ
Neoplasia; 2016 Sep; 18(9):577-83. PubMed ID: 27659017
[TBL] [Abstract][Full Text] [Related]
26. Comparison of Clinically Relevant Mutation Profiles Between Preoperative Biopsy and Corresponding Surgically Resected Specimens in Japanese Patients With Non-Small-cell Lung Cancer by Amplicon-based Massively Parallel Sequencing.
Isaka M; Serizawa M; Kenmotsu H; Koh Y; Takahashi S; Maniwa T; Wakuda K; Ono A; Naito T; Murakami H; Mori K; Endo M; Abe M; Hayashi I; Nakajima T; Yamamoto N; Takahashi T; Ohde Y
Clin Lung Cancer; 2017 Sep; 18(5):519-526.e1. PubMed ID: 28057436
[TBL] [Abstract][Full Text] [Related]
27. Sensitive and specific detection of EML4-ALK rearrangements in non-small cell lung cancer (NSCLC) specimens by multiplex amplicon RNA massive parallel sequencing.
Moskalev EA; Frohnauer J; Merkelbach-Bruse S; Schildhaus HU; Dimmler A; Schubert T; Boltze C; König H; Fuchs F; Sirbu H; Rieker RJ; Agaimy A; Hartmann A; Haller F
Lung Cancer; 2014 Jun; 84(3):215-21. PubMed ID: 24674157
[TBL] [Abstract][Full Text] [Related]
28. Tumor volume determines the feasibility of cell-free DNA sequencing for mutation detection in non-small cell lung cancer.
Ohira T; Sakai K; Matsubayashi J; Kajiwara N; Kakihana M; Hagiwara M; Hibi M; Yoshida K; Maeda J; Ohtani K; Nagao T; Nishio K; Ikeda N
Cancer Sci; 2016 Nov; 107(11):1660-1666. PubMed ID: 27575703
[TBL] [Abstract][Full Text] [Related]
29. Tumor molecular profiling of NSCLC patients using next generation sequencing.
Tsoulos N; Papadopoulou E; Metaxa-Mariatou V; Tsaousis G; Efstathiadou C; Tounta G; Scapeti A; Bourkoula E; Zarogoulidis P; Pentheroudakis G; Kakolyris S; Boukovinas I; Papakotoulas P; Athanasiadis E; Floros T; Koumarianou A; Barbounis V; Dinischiotu A; Nasioulas G
Oncol Rep; 2017 Dec; 38(6):3419-3429. PubMed ID: 29130105
[TBL] [Abstract][Full Text] [Related]
30. A highly specific and sensitive massive parallel sequencer-based test for somatic mutations in non-small cell lung cancer.
Inoue Y; Shiihara J; Miyazawa H; Ohta H; Higo M; Nagai Y; Kobayashi K; Saijo Y; Tsuchida M; Nakayama M; Hagiwara K
PLoS One; 2017; 12(4):e0176525. PubMed ID: 28448556
[TBL] [Abstract][Full Text] [Related]
31. Targeted RNA sequencing for upfront analysis of actionable driver alterations in non-small cell lung cancer.
Claerhout S; Lehnert S; Vander Borght S; Spans L; Dooms C; Wauters E; Vansteenkiste J; Weynand B; Deraedt K; Bourgain C; Vanden Bempt I
Lung Cancer; 2022 Apr; 166():242-249. PubMed ID: 35378489
[TBL] [Abstract][Full Text] [Related]
32. Non-p.V600E BRAF Mutations Are Common Using a More Sensitive and Broad Detection Tool.
Carter J; Tseng LH; Zheng G; Dudley J; Illei P; Gocke CD; Eshleman JR; Lin MT
Am J Clin Pathol; 2015 Oct; 144(4):620-8. PubMed ID: 26386083
[TBL] [Abstract][Full Text] [Related]
33. Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer.
Yu J; Kane S; Wu J; Benedettini E; Li D; Reeves C; Innocenti G; Wetzel R; Crosby K; Becker A; Ferrante M; Cheung WC; Hong X; Chirieac LR; Sholl LM; Haack H; Smith BL; Polakiewicz RD; Tan Y; Gu TL; Loda M; Zhou X; Comb MJ
Clin Cancer Res; 2009 May; 15(9):3023-8. PubMed ID: 19366827
[TBL] [Abstract][Full Text] [Related]
34. Performance analysis of SiRe next-generation sequencing panel in diagnostic setting: focus on NSCLC routine samples.
Pepe F; De Luca C; Smeraglio R; Pisapia P; Sgariglia R; Nacchio M; Russo M; Serra N; Rocco D; Battiloro C; Ambrosio F; Gragnano G; Vigliar E; Bellevicine C; Troncone G; Malapelle U
J Clin Pathol; 2019 Jan; 72(1):38-45. PubMed ID: 30279174
[TBL] [Abstract][Full Text] [Related]
35. [Screening for EGFR mutations in lung cancer by a novel real-time PCR with double-loop probe and Sanger DNA sequencing].
Zhang HP; Ruan L; Zheng LM; Bai DY; Zhang HF; Liao YQ; Ding Y
Zhonghua Zhong Liu Za Zhi; 2013 Jan; 35(1):28-32. PubMed ID: 23648296
[TBL] [Abstract][Full Text] [Related]
36. Clinical significance of multiple gene detection with a 22-gene panel in formalin-fixed paraffin-embedded specimens of 207 colorectal cancer patients.
Gao XH; Yu GY; Hong YG; Lian W; Chouhan H; Xu Y; Liu LJ; Bai CG; Zhang W
Int J Clin Oncol; 2019 Feb; 24(2):141-152. PubMed ID: 30612269
[TBL] [Abstract][Full Text] [Related]
37. Clinical application of amplicon-based next-generation sequencing to therapeutic decision making in lung cancer.
Takeda M; Sakai K; Terashima M; Kaneda H; Hayashi H; Tanaka K; Okamoto K; Takahama T; Yoshida T; Iwasa T; Shimizu T; Nonagase Y; Kudo K; Tomida S; Mitsudomi T; Saigo K; Ito A; Nakagawa K; Nishio K
Ann Oncol; 2015 Dec; 26(12):2477-82. PubMed ID: 26420428
[TBL] [Abstract][Full Text] [Related]
38. Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients.
König K; Peifer M; Fassunke J; Ihle MA; Künstlinger H; Heydt C; Stamm K; Ueckeroth F; Vollbrecht C; Bos M; Gardizi M; Scheffler M; Nogova L; Leenders F; Albus K; Meder L; Becker K; Florin A; Rommerscheidt-Fuss U; Altmüller J; Kloth M; Nürnberg P; Henkel T; Bikár SE; Sos ML; Geese WJ; Strauss L; Ko YD; Gerigk U; Odenthal M; Zander T; Wolf J; Merkelbach-Bruse S; Buettner R; Heukamp LC
J Thorac Oncol; 2015 Jul; 10(7):1049-57. PubMed ID: 26102443
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic yield of targeted next generation sequencing in various cancer types: an information-theoretic approach.
Hagemann IS; O'Neill PK; Erill I; Pfeifer JD
Cancer Genet; 2015 Sep; 208(9):441-7. PubMed ID: 26227479
[TBL] [Abstract][Full Text] [Related]
40. Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay.
Asano H; Toyooka S; Tokumo M; Ichimura K; Aoe K; Ito S; Tsukuda K; Ouchida M; Aoe M; Katayama H; Hiraki A; Sugi K; Kiura K; Date H; Shimizu N
Clin Cancer Res; 2006 Jan; 12(1):43-8. PubMed ID: 16397022
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
